National Institute for Health and Care Excellence: NICE issues final guidance endorsing Pharming's APDS therapy

This recommendation facilitates treating the activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 years and above. The oral therapy is now accessible and funded in The post NICE issues final guidance endorsing Pharming's APDS therapy appeared first on Pharmaceutical Business review.